World Health Organization Issues Concern Over Severe Lack of Weight-Loss Injections
Less than one in 10 patients eligible to benefit from GLP-1 drugs like Wegovy can access them, states the World Health Organization as it releases its first recommendations on the drugs.
Given over a billion people worldwide now obese, it is advocating for broader and more equitable access to this class of drugs.
Based on estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"Our latest guidelines affirms that excess weight is a lifelong illness that can be treated with comprehensive and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are key hurdles to universal availability to the jabs that can assist patients in reducing substantial weight, says the body.
GLP-1 Therapy Scarcity
Even under the current most favorable case, the production of these medications would only suffice for about 100 million people – under 10% of eligible patients, as stated by the WHO.
The recommendation urges countries and companies to widen access, through strategies such as licensing agreements.
A patent on the active ingredient – the primary ingredient of the drug Wegovy – is due to expire in multiple nations in 2026.
The Way Obesity Injections Function
These medications imitate a biological compound to reduce digestion speed, suppress the appetite and enhance feelings of fullness so people reduce food intake.
Patients usually start to lose weight after several weeks of starting on the regular doses.
Studies points to people may see weight return after a year of discontinuing the drug, when their usual appetite return.
To be overweight or obese raises your likelihood for experiencing health problems, like diabetes, cardiovascular issues, stroke, and certain malignancies.
Excess weight affects individuals in all nations and was linked to millions of fatalities worldwide in 2024, according to the health agency.
